Market Overview

Forest Labs Files Added Suit Related to Savella Patents

Share:

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings,
Ltd. (collectively, “Forest”) announced that Forest and Royalty Pharma
Collection Trust (“Royalty Pharma”) have jointly filed an additional
lawsuit in the U.S. District Court for the District of Delaware against
First Time US Generics LLC (“First Time”) for infringement of U.S.
Patent No. 6,602,911 (“the ‘911 patent”), U.S. Patent No. 7,888,342
(“the ‘342 patent”), and U.S. Patent No. 7,994,220 (“the ‘220 patent),
which relate to Forest's SAVELLA® product. Forest licenses
the ‘911 patent, the ‘342 patent, and the ‘220 patent from Royalty
Pharma. The ‘911 patent expires in January 2023, the ‘342 patent expires
in November 2021, and the ‘220 patent expires in September 2029.

Forest

See full press release

Posted-In: News

 

Related Articles (FRX)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

OCZ Tech Reports Settlement of Class Action Suit, to Pay $7.5M

Bob Moriarty: Ignore the Noise and Profit from Gold's Volatility